Abstract
For kidney cancer, ESMO 2026 has one of its most concentrated programmes in years. Nearly all of the practice-relevant renal data come on a single day, Sunday, October 25. The morning Proffered Paper session puts both phase 3 belzutifan readouts, a randomized trial in oligometastatic disease and two first-in-class agents into 90 minutes. The afternoon Rapid Oral session covers the adjuvant setting, non-clear cell disease and a set of biomarker and imaging studies. This preview is written from the final programme, before results are public. It does not report data. It sets out what each study was designed to answer, what we already know going in, and what would change practice if the results hold.
EUVIMED